Mechanism of anti-β-adrenoceptor antibody mediated myocardial damage in dilated cardiomyopathy

Liao Yuhua , Cheng Longxian , Tu Yuanshu , Zhang Jinzhi , Dong Jihua , Li Shuli , Tian Yuan , Peng Youhong

Current Medical Science ›› 1997, Vol. 17 ›› Issue (1) : 5 -8.

PDF
Current Medical Science ›› 1997, Vol. 17 ›› Issue (1) : 5 -8. DOI: 10.1007/BF02887992
Article

Mechanism of anti-β-adrenoceptor antibody mediated myocardial damage in dilated cardiomyopathy

Author information +
History +
PDF

Abstract

Antibodies against β1-adrenoceptor can be detected in serum of patients with dilated cardiomyopathy (DCM), which have β-agonist-like activity, and induce a positive chronotropic effect on cardiac myocytes by its persistence at full strength. Effects of the antibodies against β-adrenoceptor from sera of patients with DCM on myocardial cytotoxicity and cytoplasmic free Ca2+-concentration ([Ca2+]i) were observed in the cultured single layer SD rat ventricular cells by using the cytotoxicity assay and fluorescent Ca2+- indicator fura-2/AM. The positive sera of the anti-β-adrenoceptor antibodies from patients with DCM markedly enhanced myocardial [Ca2+]i. Betaloc, a βi-receptor blocker, might inhibit the increase of the antibody-mediated myocardial [Ca2+]i, and the sera from healthy donors had no effect on myocardial [Ca2+]i. Our results suggest that the anti-β-adrenoceptor antibody might increase myocardial [Ca2+]i and result in myocardial damage. The antibodies might activate receptor-gating [Ca2+]-channel, thereby causing myocardial [Ca2+]i rise and calcium overload. Early use of betaloc is recommended in the treatment of dilated cardiomyopathy.

Keywords

antibodies / β-adrenoceptor / cytoplasmic free calcium / fura-2/AM / dilated cardiomyopathy

Cite this article

Download citation ▾
Liao Yuhua, Cheng Longxian, Tu Yuanshu, Zhang Jinzhi, Dong Jihua, Li Shuli, Tian Yuan, Peng Youhong. Mechanism of anti-β-adrenoceptor antibody mediated myocardial damage in dilated cardiomyopathy. Current Medical Science, 1997, 17(1): 5-8 DOI:10.1007/BF02887992

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

LimasC J, LimasC. Immune-mediated modulation of β-adrenoceptor function in human dilated cardiomyopathy. Clin Immunnol Immunopathol, 1993, 68: 204-204

[2]

WollenbergerA, WallukatG. Anti-β-adrenoceptors auto-antibodies from patients with myocarditis and dilated cardiomyopathy: β-adrenergic agonist activity without desensitization. J Mol Cell Cardiol, 1989, 21(Supp I): 67-67

[3]

WallukatG, MorwinskiM, KowalK, et al.. Autoantibodies against the β-adrenergic receptor in human myocarditis and dilated cardiomyopathy: β-adrenergic agonism without desensitization. Eur Heart J, 1991, 12(Suppl D): 178-178

[4]

RosenbaumM B, ChialeP A, SchejtmanD, et al.. Antibnodies to Betaadrenergic receptors disclosing agonist-like properties in idiopathic dilated cardiomyopathy and Chargas heart disease. J Cardiovasc Electrophysiol, 1994, 5: 367-367

[5]

MagnussonY, WallukatG, WaagsteinF, et al.. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the βadrenoceptor with positive chronotropic effect. Circulation, 1994, 89: 2760-2760

[6]

1994,74:375

[7]

ADP/ATP 1995, 11:211

[8]

ADP/ATP, 1995, 11:335

[9]

BahouthS W, MalbonC C. Human β-adrenergic receptors: Simultaneous purification of β1 and β2-adrenergic receptor peptides. Biochem J, 1987, 248: 557-557

[10]

KaumannA J. Some aspects of heart beta adrenoceptor function. Cardiovasc Drugs Therapy, 1991, 5: 549-549

AI Summary AI Mindmap
PDF

98

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/